Hydroxyzine Should Be Avoided in Patients with Atrial Fibrillation Due to Significant Cardiac Risk
Hydroxyzine is not safe for patients with atrial fibrillation and should be avoided due to documented QT prolongation, risk of torsades de pointes, and potential for dangerous arrhythmias, particularly when combined with antiarrhythmic medications commonly used in AF management.
Critical Safety Concerns from FDA Labeling
The FDA drug label for hydroxyzine explicitly warns about QT prolongation and torsades de pointes (TdP) in post-marketing surveillance 1. Most critically, the label states that hydroxyzine "should be used with caution in patients with risk factors for QT prolongation...as well as recent myocardial infarction, uncompensated heart failure, and bradyarrhythmias" 1.
Patients with atrial fibrillation inherently meet multiple high-risk criteria:
- Many have underlying heart disease
- Frequently have electrolyte imbalances
- Commonly take concomitant arrhythmogenic drugs
Dangerous Drug Interactions with Standard AF Therapies
The FDA label specifically warns about caution during concomitant use with Class IA (quinidine, procainamide) or Class III (amiodarone, sotalol) antiarrhythmics 1—the exact medications recommended by ACC/AHA/ESC guidelines for AF management 2.
This creates a direct contraindication scenario: The 2006 ACC/AHA/ESC guidelines recommend amiodarone, sotalol, procainamide, and other QT-prolonging agents as standard therapy for AF rate control and cardioversion 2. Combining hydroxyzine with these agents substantially increases arrhythmic risk.
Clinical Evidence of Harm
A 2016 case report documented a 65-year-old woman with atrial fibrillation who developed QT prolongation and torsades de pointes when hydroxyzine was combined with flecainide (a Class IC antiarrhythmic commonly used for AF) 3. The authors concluded that "concomitant administration of flecainide and H1 receptor antagonists seems to have a synergistic effect in QT interval prolongation and subsequent TdP" and that "concurrent administration of H1 receptor antagonists to patients receiving class Ic anti-arrhythmic drugs should be avoided" 3.
Additional case reports document:
- Supraventricular tachycardia induced by hydroxyzine 4
- Abnormal ventricular repolarization with substantial doses 5
Why This Matters for AF Patients Specifically
AF patients are uniquely vulnerable because:
Polypharmacy is standard: The 2014 AHA/ACC/HRS guidelines recommend beta-blockers, calcium channel blockers, digoxin, or amiodarone for rate control 6, and the 2024 ESC guidelines emphasize combination therapy when single agents fail 7
Underlying cardiac disease: Most AF patients have hypertension, heart failure, or coronary disease—all risk factors that the FDA label identifies as requiring caution with hydroxyzine 1
Electrolyte disturbances: AF patients on diuretics or with heart failure commonly have hypokalemia or hypomagnesemia, further increasing TdP risk
Age considerations: The FDA label notes that elderly patients (common in AF populations) should start on low doses and be observed closely due to increased risk of confusion and oversedation 1
Practical Clinical Algorithm
If a patient with AF requires antihistamine therapy:
First choice: Use a second-generation antihistamine (cetirizine, loratadine, fexofenadine) that lacks significant cardiac effects—though note the FDA label warns to "avoid cetirizine or levocetirizine in patients who have experienced...hypersensitivity reactions with hydroxyzine, due to the risk of cross-sensitivity" 1
Check baseline QTc: If hydroxyzine must be used despite risks, obtain baseline ECG and measure QTc interval
Review medication list: Identify all QT-prolonging drugs, particularly antiarrhythmics
Monitor electrolytes: Ensure potassium >4.0 mEq/L and magnesium >2.0 mg/dL
Use lowest effective dose: Start at the low end of dosing range, particularly in elderly patients 1
Avoid combination with Class I or III antiarrhythmics: This is the highest-risk scenario based on FDA warnings and case reports 1, 3
Common Pitfall to Avoid
Do not assume hydroxyzine is "just an antihistamine" with minimal cardiac effects. The documented cases of TdP, the FDA black-box-level warnings about QT prolongation, and the specific caution against use with antiarrhythmics make this a high-risk medication in the AF population. The fact that one case report showed synergistic effects with flecainide—a commonly prescribed AF medication—should raise immediate red flags 3.
The 2006 ACC/AHA/ESC guidelines make no mention of hydroxyzine as a therapeutic option for AF management, and for good reason 2. The 2024 ESC guidelines emphasize rate control with beta-blockers, diltiazem, verapamil, or digoxin as first-line agents 7—none of which include hydroxyzine.
Bottom line: Hydroxyzine carries documented cardiac risks that are amplified in AF patients taking standard antiarrhythmic therapy. Alternative antihistamines with safer cardiac profiles should be strongly preferred.